Abstract:The intestine harbors a large population of microorganisms that interact with epithelial cells to maintain host healthy physiological status. These intestinal microbiota engage in the fermentation of non-digestible nutrients and produce beneficial metabolites to regulate host homeostasis, metabolism, and immune response. The disruption of microbiota, known as dysbiosis, has been implicated in many intestinal diseases, including colorectal cancer (CRC). As the third most common cancer and the second leading cause of cancer-related death worldwide, CRC poses a significant health burden. There is an urgent need for novel interventions to reduce CRC incidence and improve clinical outcomes. Modulating the intestinal microbiota has emerged as a promising approach for CRC prevention and treatment. Current research efforts in CRC probiotics primarily focus on reducing the incidence of CRC, alleviating treatment-related side effects, and potentiating the efficacy of anticancer therapy, which is the key to successful translation to clinical practice. This paper aims to review the traditional probiotics and new interventions, such as next-generation probiotics and postbiotics, in the context of CRC. The underlying mechanisms of probiotic anti-cancer effects are also discussed, including the restoration of microbial composition, reinforcement of gut barrier integrity, induction of cancer cell apoptosis, inactivation of carcinogens, and modulation of host immune response. This paper further evaluates the novel strategy of probiotics as an adjuvant therapy in boosting the efficacy of chemotherapy and immunotherapy. Despite all the promising findings presented in studies, the evaluation of potential risks, optimization of delivery methods, and consideration of intra-patient variability of gut microbial baseline must be thoroughly interpreted before bench-to-bedside translation.

Targeting the gut microbiota: a new strategy for colorectal cancer treatment

Research progress of intestinal microbiota in targeted therapy and immunotherapy of colorectal cancer

Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer

Gut microbiota modulation: a tool for the management of colorectal cancer

Therapeutic approaches to colorectal cancer via strategies based on modulation of gut microbiota

Microbe-based management for colorectal cancer

Gut microbiota: A novel and potential target for radioimmunotherapy in colorectal cancer

Gut microbiota and colorectal cancer: insights into pathogenesis for novel therapeutic strategies

Correlation of Pathogenesis, Early Diagnosis and Treatment of Colorectal Cancer with Microorganisms

Strategies for the treatment of colorectal cancer caused by gut microbiota

Interaction of gut microbiota with the tumor microenvironment: A new strategy for antitumor treatment and traditional Chinese medicine in colorectal cancer

Effect of gut microbiota in the colorectal cancer and potential target therapy

Gut microbiome in tumorigenesis and therapy of colorectal cancer

The challenge and opportunity of gut microbiota‐targeted nanomedicine for colorectal cancer therapy

Role of Gut Microbiota in the Development and Treatment of Colorectal Cancer

Gut microbiota interactions with antitumor immunity in colorectal cancer: From understanding to application

Bidirectional effects of intestinal microbiota and antibiotics: a new strategy for colorectal cancer treatment and prevention

Gut microbiota: An emerging therapeutic approach of herbal medicine for prevention of colorectal cancer

Probiotics intervention in colorectal cancer: From traditional approaches to novel strategies

Colorectal cancer and gut microbiota studies in China

Beneficial insights into postbiotics against colorectal cancer